ACP
OLMA icon

Acuta Capital Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Acuta Capital Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-153,007
Closed -$1.89M – 51
2023
Q3 		$1.89M Buy
153,007
+47,193
+45% +$481K 1.27% 25
2023
Q2 		$956K Buy
+105,814
New +$639K 0.65% 29
2021
Q4 		– Sell
-150,500
Closed -$4.15M – 49
2021
Q3 		$4.15M Buy
+150,500
New +$4.06M 1.46% 20

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acuta Capital Partners's OLMA Position: Q4 2023 in Review

Acuta Capital Partners sold out of Olema Pharmaceuticals (OLMA) in Q4 2023, closing a stake of 153,007 shares — an estimated $1.89M sold.

Acuta Capital Partners first reported a position in OLMA in Q3 2021 and held it in 3 quarters. The position peaked at $4.15M in Q3 2021. 113 funds tracked by Wall St. Rank hold OLMA as of Q4 2023.

  • Acuta Capital Partners reported no remaining Olema Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 153,007 Olema Pharmaceuticals shares in Q4 2023, an estimated $1.89M.
  • Acuta Capital Partners first reported a position in Olema Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Acuta Capital Partners's Olema Pharmaceuticals position peaked at $4.15M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2023.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.